

Otto Mayer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6234983/publications.pdf>

Version: 2024-02-01

92
papers

1,498
citations

279487

23
h-index

344852

36
g-index

95
all docs

95
docs citations

95
times ranked

2742
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognosis and therapeutic management of patients hospitalized for heart failure in 2010-2020. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2022, 166, 312-321.	0.2	2
2	The mortality risk of patients hospitalized for ischemic stroke between 2003 and 2019. Vnitřni Lekarství, 2022, 68, E04-E11.	0.1	0
3	High leptin status indicates an increased risk of mortality and heart failure in stable coronary artery disease. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 2137-2146.	1.1	1
4	The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker?. Journal of Human Hypertension, 2021, 35, 240-249.	1.0	14
5	The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 29-35.	0.6	3
6	The coincidence of low vitamin K status and high expression of growth differentiation factor 15 may indicate increased mortality risk in stable coronary heart disease patients. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 540-551.	1.1	6
7	Reference values of retinal microcirculation parameters derived from a population random sample. Microvascular Research, 2021, 134, 104117.	1.1	5
8	Serum biomarkers, skin autofluorescence and other methods. Which parameter better illustrates the relationship between advanced glycation end products and arterial stiffness in the general population?. Hypertension Research, 2021, 44, 518-527.	1.5	14
9	The prognostic impact of renal function decline during hospitalization for myocardial infarction. Journal of Comparative Effectiveness Research, 2021, 10, 219-228.	0.6	3
10	A novel nonsense mutation in the β -subunit of the epithelial sodium channel causing Liddle syndrome. Blood Pressure, 2021, 30, 291-299.	0.7	5
11	Uricemia in the acute phase of myocardial infarction and its relation to long-term mortality risk. Journal of Comparative Effectiveness Research, 2021, 10, 979-988.	0.6	0
12	Long-term trends in the incidence, treatment, hospital fatality and subsequent mortality from acute myocardial infarction in the Czech Republic. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2021, 165, 283-290.	0.2	1
13	Blood pressure control in the general and high risk populations, longitudinal trends. European Heart Journal, 2021, 42, .	1.0	0
14	Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients. Biomarkers in Medicine, 2021, 15, 1465-1477.	0.6	1
15	The prognostic importance of subclinical heart failure in stable coronary heart disease patients. Acta Cardiologica, 2020, 75, 329-336.	0.3	4
16	Mood disorders impaired quality of life but not the mortality or morbidity risk in stable coronary heart disease patients. Acta Cardiologica, 2020, 75, 667-675.	0.3	8
17	Soluble RAGEs and cardiovascular risk factors in adult offspring of patients with premature coronary heart disease. Blood Pressure, 2020, 29, 87-94.	0.7	2
18	Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness. Hypertension Research, 2020, 43, 111-120.	1.5	9

#	ARTICLE	IF	CITATIONS
19	Comparison of three office blood pressure measurement techniques and their effect on hypertension prevalence in the general population. <i>Journal of Hypertension</i> , 2020, 38, 656-662.	0.3	15
20	miR-133a AND myocardial ischemia/reperfusion injury. Response to letter by Wang. <i>International Journal of Cardiology</i> , 2020, 299, 255.	0.8	0
21	Is There Really an Association of High Circulating Adiponectin Concentration and Mortality or Morbidity Risk in Stable Coronary Artery Disease?. <i>Hormone and Metabolic Research</i> , 2020, 52, 861-868.	0.7	2
22	Which serum uric acid levels are associated with increased cardiovascular risk in the general adult population?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 897-905.	1.0	4
23	30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985 – 2016/17. <i>PLoS ONE</i> , 2020, 15, e0232845.	1.1	34
24	Systematic COronary Risk Evaluation (SCORE) and 20-year risk of cardiovascular mortality and cancer. <i>European Journal of Internal Medicine</i> , 2020, 79, 63-69.	1.0	3
25	Synergistic effect of sclerostin and angiotensin II receptor 1 polymorphism on arterial stiffening. <i>Biomarkers in Medicine</i> , 2020, 14, 173-184.	0.6	1
26	Response to letter by Yu and Chen. <i>International Journal of Cardiology</i> , 2020, 298, 120.	0.8	0
27	Reply. <i>Journal of Hypertension</i> , 2020, 38, 1860-1861.	0.3	0
28	Time trends in the relation between the achieved education and the cardiovascular risk factors prevalence and control in general population and in persons with coronary heart disease. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
29	Title is missing!. , 2020, 15, e0232845.		0
30	Title is missing!. , 2020, 15, e0232845.		0
31	Title is missing!. , 2020, 15, e0232845.		0
32	Title is missing!. , 2020, 15, e0232845.		1
33	The low expression of circulating microRNA-19a represents an additional mortality risk in stable patients with vascular disease. <i>International Journal of Cardiology</i> , 2019, 289, 101-106.	0.8	26
34	P5530The low expression of circulating microRNA-19a represents an additional mortality risk in stable patients with vascular disease. <i>European Heart Journal</i> , 2019, 40, .	1.0	1
35	To what extent can the chosen blood pressure measurement technique affect the outcomes of an observational survey?. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 841-852.	0.6	0
36	Response to letter by Chen and colleagues. <i>International Journal of Cardiology</i> , 2019, 297, 119.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry. Journal of Hypertension, 2019, 37, 2015-2023.	0.3	7
38	The changes in achievement of target LDL-cholesterol levels between 2006 and 2017 in Czech patients with chronic coronary heart disease. Cor Et Vasa, 2019, 61, 20-27.	0.1	1
39	Serum Vitamin D Status, Vitamin D Receptor Polymorphism, and Glucose Homeostasis in Healthy Subjects. Hormone and Metabolic Research, 2018, 50, 56-64.	0.7	9
40	Prospective study of metabolic syndrome as a mortality marker in chronic coronary heart disease patients. European Journal of Internal Medicine, 2018, 47, 55-61.	1.0	10
41	The changes in cardiovascular prevention practice between 1995-2017 in the Czech Republic: a comparison of EUROASPIRE I, II, III, IV and V study. Vnitřní Lekarství, 2018, 64, 1190-1199.	0.1	3
42	Synergistic effect of low K and D vitamin status on arterial stiffness in a general population. Journal of Nutritional Biochemistry, 2017, 46, 83-89.	1.9	16
43	P902Should the treatment of patients with established coronary heart disease and hyperglycaemia be extended by a random administration of antidiabetics?. European Heart Journal, 2017, 38, .	1.0	0
44	A comparison of secondary prevention practice inÂpoststroke and coronary heart disease patients. Public Health, 2016, 137, 64-72.	1.4	5
45	The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease. International Journal of Cardiology, 2016, 203, 916-922.	0.8	24
46	Desphospho-uncarboxylated matrix Gla protein is associated with increased aortic stiffness in a general population. Journal of Human Hypertension, 2016, 30, 418-423.	1.0	55
47	Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. Blood Pressure, 2016, 25, 228-234.	0.7	131
48	Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population. Hypertension Research, 2016, 39, 266-271.	1.5	22
49	Educational level and risk profile and risk control in patients with coronary heart disease. European Journal of Preventive Cardiology, 2016, 23, 881-890.	0.8	33
50	Low blood pressure during the acute period of ischemic stroke is associated with decreased survival. Journal of Hypertension, 2015, 33, 339-345.	0.3	50
51	Blood pressure control and risk profile in poststroke survivors. Journal of Hypertension, 2015, 33, 2107-2114.	0.3	9
52	Differential effect of metabolic syndrome on various parameters of arterial stiffness. Blood Pressure, 2015, 24, 206-211.	0.7	5
53	Association between endothelial NO synthase polymorphisms and arterial properties in the general population. Nitric Oxide - Biology and Chemistry, 2015, 44, 47-51.	1.2	11
54	The Obesity Paradox and Survivors of Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1443-1450.	0.7	42

#	ARTICLE	IF	CITATIONS
55	Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1354-1362.	0.8	81
56	Tobacco smoking strongly modifies the association of prothrombin G20210A with undetermined stroke: Consecutive survivors and population-based controls. <i>Atherosclerosis</i> , 2015, 240, 446-452.	0.4	9
57	Quality of Life Predictors in Chronic Stable Post-Stroke Patients and Prognostic Value of SF-36 Score as a Mortality Surrogate. <i>Translational Stroke Research</i> , 2015, 6, 375-383.	2.3	26
58	The association between uncarboxylated matrix Gla protein and lipoprotein-associated phospholipase A2. <i>Maturitas</i> , 2015, 80, 82-88.	1.0	4
59	The predictive potential of asymptomatic mild elevation of cardiac troponin I on mortality risk of stable patients with vascular disease. <i>Clinical Biochemistry</i> , 2015, 48, 353-357.	0.8	1
60	Positive effects of antihypertensive treatment on aortic stiffness in the general population. <i>Hypertension Research</i> , 2014, 37, 64-68.	1.5	17
61	Comparison of Noninvasive Assessments of Central Blood Pressure Using General Transfer Function and Late Systolic Shoulder of the Radial Pressure Wave. <i>American Journal of Hypertension</i> , 2014, 27, 162-168.	1.0	12
62	Unexpected inverse relationship between impaired glucose metabolism and lipoprotein-associated phospholipase A2 activity in patients with stable vascular disease. <i>European Journal of Internal Medicine</i> , 2014, 25, 556-560.	1.0	11
63	Desphospho-uncarboxylated matrix Gla-protein is associated with mortality risk in patients with chronic stable vascular disease. <i>Atherosclerosis</i> , 2014, 235, 162-168.	0.4	75
64	Large artery stiffness and carotid flow pulsatility in stroke survivors. <i>Journal of Hypertension</i> , 2014, 32, 1097-1103.	0.3	26
65	Hypertriglyceridemic waist increased risk of inappropriate glucose control in patients with coronary heart disease. <i>Clinical Lipidology</i> , 2014, 9, 515-522.	0.4	2
66	Residual risk of cardiovascular mortality in patients with coronary heart disease: The EUROASPIRE Risk Categories. <i>International Journal of Cardiology</i> , 2013, 168, 910-914.	0.8	28
67	Arterial stiffness parameters: How do they differ?. <i>Atherosclerosis</i> , 2013, 231, 359-364.	0.4	33
68	The association between low 25-hydroxyvitamin D and increased aortic stiffness. <i>Journal of Human Hypertension</i> , 2012, 26, 650-655.	1.0	39
69	An inverse association between serum leptin concentration and reported alcohol intake in patients with manifest vascular disease. <i>European Journal of Clinical Nutrition</i> , 2010, 64, 1350-1357.	1.3	2
70	Laboratory Evaluation of Antiphospholipid Antibodies in Patients With Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 318-325.	0.7	17
71	The assessment of carotid-femoral distance for aortic pulse wave velocity: Should it be estimated from body height? <i>Artery Research</i> , 2010, 4, 19.	0.3	7
72	The Interaction of Endothelial Nitric Oxide Synthase Polymorphism and Current Smoking in Terms of Increased Arterial Stiffness. <i>Physiological Research</i> , 2010, 59, 529-536.	0.4	14

#	ARTICLE	IF	CITATIONS
73	N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure. <i>European Journal of Epidemiology</i> , 2009, 24, 363-368.	2.5	18
74	Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1. <i>Physiological Research</i> , 2009, 58, 179-184.	0.4	22
75	Synergistic effect of angiotensin II type 1 receptor and endothelial nitric oxide synthase gene polymorphisms on arterial stiffness. <i>Journal of Human Hypertension</i> , 2008, 22, 111-118.	1.0	12
76	Even mild changes in free thyroxine could influence the degree of heart failure measured by its biological surrogates. <i>Physiological Research</i> , 2008, 57, 525-529.	0.4	6
77	The quality of secondary prevention of coronary heart disease in Czech patients in the EURO-ASPIRE III survey.. <i>Cor Et Vasa</i> , 2008, 50, 156-162.	0.1	13
78	The standard of secondary prevention of stroke in Czech patients in the EUROASPIRE III Study - Stroke Specific Module. <i>Cor Et Vasa</i> , 2008, 50, 446-454.	0.1	10
79	Mild hyperhomocysteinaemia is associated with increased aortic stiffness in general population. <i>Journal of Human Hypertension</i> , 2006, 20, 267-271.	1.0	33
80	Hypothyroidism in coronary heart disease and its relation to selected risk factors. <i>Vascular Health and Risk Management</i> , 2006, 2, 499-506.	1.0	38
81	Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates. <i>Physiological Research</i> , 2006, 55, 475-81.	0.4	8
82	Fibrate treatment and prevalence risk of mild hyperhomocysteinaemia in clinical coronary heart disease patients. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2004, 11, 244-249.	3.1	5
83	Educational level and risk profile of cardiac patients in the EUROASPIRE II substudy. <i>Journal of Epidemiology and Community Health</i> , 2004, 58, 47-52.	2.0	49
84	Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 367-371.	0.8	28
85	Treatment of Hyperhomocysteinemia with Folic Acid: Effects on Homocysteine Levels, Coagulation Status, and Oxidative Stress Markers. <i>Journal of Cardiovascular Pharmacology</i> , 2002, 39, 851-857.	0.8	32
86	The effects of folate supplementation on some coagulation parameters and oxidative status surrogates. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 1-5.	0.8	35
87	The pursuit of secondary prevention targets in Czech coronary patients. A comparison of EuroAspire I and II surveys. <i>Central European Journal of Public Health</i> , 2002, 10, 107-11.	0.4	0
88	A population study of the influence of beer consumption on folate and homocysteine concentrations. <i>European Journal of Clinical Nutrition</i> , 2001, 55, 605-609.	1.3	66
89	Insulin-mediated glucose disposal is decreased in normal subjects with relatively low plasma magnesium concentrations. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 418-420.	1.5	65
90	Effect of Variations in Plasma Magnesium Concentration on Resistance to Insulin-Mediated Glucose Disposal in Nondiabetic Subjects¹. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3783-3785.	1.8	50

#	ARTICLE	IF	CITATIONS
91	Isradipine in the Treatment of Hypertension. American Journal of Hypertension, 1991, 4, 140S-143S.	1.0	5
92	Small and large doses of guanfacine (Estulic Sandoz) in the treatment of hypertension. Cor Et Vasa, 1987, 29, 37-41.	0.1	0